RTTNews | Aug 3, 2020 10:03AM EDT

10:02 Monday, August 3, 2020 (RTTNews.com) - Shares of Co-Diagnostics, Inc. (CODX) jumped 15% on Monday morning after the company announced it received FDA's emergency use authorization for its Covid-19 test.

CODX is currently trading at $27.49, up $3.49 or 14.55%, on the Nasdaq.

Co-Diagnostics said its partner, Clinical Reference Laboratory has FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics' patented CoPrimer technology.

Read the original article on RTTNews ( https://www.rttnews.com/3117428/stock-alert-co-diagnostics-up-15-on-covid-19-test-approval.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved